Bronchial neoplasm

Summary

Bronchial neoplasm (MONDO:0002807) is a cancer (an umbrella term covering 5 Mondo subtypes) and 22 clinical trials. Top therapeutic interventions include carboplatin, alectinib, and pemetrexed. A subtype of bronchial disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 5 Mondo subtypes
• Clinical trials: 22

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bronchial neoplasm
Mondo ID	MONDO:0002807
EFO	EFO:1000849
MeSH	D001984
DOID	DOID:3906
SNOMED CT	126705004
UMLS	C0006264
MedGen	2735
Anatomy (UBERON)	UBERON:0002185
Is cancer (heuristic)	yes

Also known as: bronchial neoplasm · bronchial neoplasm (disease) · bronchus neoplasm (disease) · bronchus tumor · bronchus tumour · neoplasm of bronchus · tumor of bronchus · tumour of bronchus

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of bronchial disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › bronchial disorder › bronchial neoplasm

Related subtypes (5): bronchitis, bronchiectasis, asthma, non-syndromic bridging bronchus, non-syndromic congenital bronchial atresia

Subtypes (5): endobronchial lipoma, bronchus cancer, bronchus adenoma, endobronchial leiomyoma, bronchial endocrine tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

2 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Alectinib	Phase 2
Icotinib	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 22.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	10
PHASE1	6
PHASE2	4
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03402048	PHASE3	UNKNOWN	The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial
NCT06177925	PHASE2	RECRUITING	A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
NCT02050724	PHASE2	TERMINATED	ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT
NCT02264210	PHASE2	COMPLETED	Icotinib for Completed Resected IB NSCLC With EGFR Mutation
NCT03037385	PHASE1/PHASE2	COMPLETED	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
NCT04644315	PHASE2	TERMINATED	A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
NCT02897778	PHASE1	COMPLETED	Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
NCT02909452	PHASE1	COMPLETED	Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
NCT03516214	PHASE1	COMPLETED	EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations
NCT04862780	PHASE1	TERMINATED	(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
NCT05153408	PHASE1	TERMINATED	(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
NCT05241873	PHASE1	TERMINATED	(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
NCT06376084	Not specified	ACTIVE_NOT_RECRUITING	Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
NCT06494241	Not specified	ACTIVE_NOT_RECRUITING	Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
NCT01261585	Not specified	COMPLETED	Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT
NCT01802203	Not specified	COMPLETED	trūFreeze® Spray Cryotherapy Patient Registry
NCT02493023	Not specified	COMPLETED	Automatic CT-to-patient Registration During Navigated Bronchoscopy and EBUS
NCT02745002	Not specified	COMPLETED	Navigated EBUS and Functional Imaging in Lung Cancer
NCT02804100	Not specified	UNKNOWN	Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients
NCT03745859	Not specified	TERMINATED	Evaluation of a New Open Source Virtual Bronchoscope Navigation System
NCT03892408	Not specified	COMPLETED	High-flow Nasal Oxygen During Rigid Bronchoscopy Under General Anesthesia: a Randomized Controlled Trial
NCT06531265	Not specified	COMPLETED	Cryotechnique as a Diagnostic and Therapeutic Tool of Endobronchial Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CARBOPLATIN	4	4
ALECTINIB	4	1
PEMETREXED	4	1
PRALSETINIB	4	1
VINORELBINE	4	1
ENTINOSTAT	3	2
ADEBRELIMAB	3	1
ICOTINIB	3	1
NAZARTINIB	2	1
PEBEZERTINIB	2	1
TIGOZERTINIB	2	1
CHEMBL4297597	0	1